Search

Your search keyword '"Rodriguez Galindo, Carlos"' showing total 17 results
Start Over Author "Rodriguez Galindo, Carlos" Journal blood
17 results on '"Rodriguez Galindo, Carlos"'

2. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

Author

Emile, Jean-François, Abla, Oussama, Fraitag, Sylvie, Horne, Annacarin, Haroche, Julien, Donadieu, Jean, Requena-Caballero, Luis, Jordan, Michael B., Abdel-Wahab, Omar, Allen, Carl E., Charlotte, Frédéric, Diamond, Eli L., Egeler, R.Maarten, Fischer, Alain, Herrera, Juana Gil, Henter, Jan-Inge, Janku, Filip, Merad, Miriam, Picarsic, Jennifer, Rodriguez-Galindo, Carlos, Rollins, Barret J., Tazi, Abdellatif, Vassallo, Robert, and Weiss, Lawrence M.

Published
2016
Full Text
View/download PDF

3. Evaluation of Early Treatment Response Utilizing the MAS-ALL18 Adapted Management Guideline in Four "Mexico in Alliance with St. Jude" (MAS) Member Hospitals

Author

Romo, Hugo, primary, Gonzalez-Montalvo, Pablo, additional, Arce, Daniela, additional, Aguilar-Escobar, Dinora, additional, Mercado, Nataly, additional, Echeandia, Naomi, additional, Guerrero Gómez, Karla Nohemi, additional, Rodriguez-Galindo, Carlos, additional, and Friedrich, Paola M., additional

Published
2021
Full Text
View/download PDF

4. Molecular and MRD-Based Characterization of Acute Lymphoblastic Leukemia in Mexico: Experience from the Mexico in Alliance with St. Jude "Bridge Project"

Author

Aguilar, Dinora Virginia, primary, Gonzalez-Montalvo, Pablo, additional, Romo, Hugo, additional, Arce, Daniela, additional, Gonzalez-Zamorano, Margarita, additional, Lopez-Ruiz, Mayra Ivette, additional, Loeza Oliva, José De Jesús, additional, Mercado, Nataly, additional, Echeandia, Naomi, additional, Guerrero Gómez, Karla Nohemi, additional, Vega, Lourdes, additional, Garay, Sergio, additional, Castro, Martha Fabiola, additional, Jarquín-Ramirez, Berenice, additional, Ramírez-Martinez, Elizabeth Candy, additional, Ortiz-Gálvez, Víctor Manuel, additional, Rivera-Sanchez, Netzi, additional, Rodriguez-Galindo, Carlos, additional, and Friedrich, Paola M., additional

Published
2021
Full Text
View/download PDF

5. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective

Author

Bolous, Nancy S., primary, Chen, Yichen, additional, Wang, Huiqi, additional, Davidoff, Andrew M., additional, Devidas, Meenakshi, additional, Jacobs, Timothy W., additional, Meagher, Michael M., additional, Nathwani, Amit C., additional, Neufeld, Ellis J., additional, Piras, Bryan A., additional, Rodriguez-Galindo, Carlos, additional, Reiss, Ulrike M., additional, and Bhakta, Nickhill, additional

Published
2021
Full Text
View/download PDF

7. Clinical Outcomes and Molecular Responses in Children with Langerhans Cell Histiocytosis Treated with MAPK Pathway Inhibitors

Author

Eckstein, Olive S., primary, Zinn, Daniel, additional, Fein Levy, Carolyn, additional, Henry, Michael M., additional, Campbell, Patrick, additional, Jordan, Michael B., additional, Kumar, Ashish R, additional, Rodriguez-Galindo, Carlos, additional, Hijiya, Nobuko, additional, Abla, Oussama, additional, McClain, Kenneth L., additional, and Allen, Carl E., additional

Published
2018
Full Text
View/download PDF

12. Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

Author

Arceci, Robert J., primary, Allen, Carl E., additional, Dunkel, Ira, additional, Jacobsen, Eric D., additional, Whitlock, James, additional, Vassallo, Robert, additional, Borrello, Ivan M., additional, Oliff, Allen, additional, Morris, Shannon R., additional, Ann M Reedy, Beth, additional, Portnoy, Alison, additional, Smith, Deborah A., additional, Noble, Bob, additional, Murnane, Amy A., additional, Szabo, Stephen A., additional, Rodriguez-Galindo, Carlos, additional, Heaney, Mark L., additional, McClain, Kenneth L., additional, and Vaseilbuh, Sarah, additional

Published
2013
Full Text
View/download PDF

13. Molecular and MRD-Based Characterization of Acute Lymphoblastic Leukemia in Mexico: Experience from the Mexico in Alliance with St. Jude“Bridge Project”

Author

Aguilar, Dinora Virginia, Gonzalez-Montalvo, Pablo, Romo, Hugo, Arce, Daniela, Gonzalez-Zamorano, Margarita, Lopez-Ruiz, Mayra Ivette, Loeza Oliva, José De Jesús, Mercado, Nataly, Echeandia, Naomi, Guerrero Gómez, Karla Nohemi, Vega, Lourdes, Garay, Sergio, Castro, Martha Fabiola, Jarquín-Ramirez, Berenice, Ramírez-Martinez, Elizabeth Candy, Ortiz-Gálvez, Víctor Manuel, Rivera-Sanchez, Netzi, Rodriguez-Galindo, Carlos, and Friedrich, Paola M.

Published
2021
Full Text
View/download PDF

14. Evaluation of Early Treatment Response Utilizing the MAS-ALL18 Adapted Management Guideline in Four “Mexico in Alliance with St. Jude”(MAS) Member Hospitals

Author

Romo, Hugo, Gonzalez-Montalvo, Pablo, Arce, Daniela, Aguilar-Escobar, Dinora, Mercado, Nataly, Echeandia, Naomi, Guerrero Gómez, Karla Nohemi, Rodriguez-Galindo, Carlos, and Friedrich, Paola M.

Abstract

Introduction:Acute lymphoblastic leukemia (ALL) represents approximately 50% of all childhood cancers in Latin America. Mexico is not the exception. The impact of ALL survival on overall childhood cancer survival is significant. According to government data, five-year survival is about 52%. Mexico in Alliance with St. Jude (MAS) is a multi-site, intersectoral collaboration. The collaborative network has explored and reported on factors associated with this suboptimal outcome and have identified challenges with ALL risk group classification as a leading cause. For example, as many as 82% of children diagnosed with ALL in Mexico receive high-risk treatment and the tendency for higher-risk group assignment often occurs in response to limited access to cytogenetic testing and minimal residual disease (MRD) testing. This leads to higher intensity treatment and may explain the high rate of treatment-related death (TRD) (12%) documented during the induction but also subsequently. In our previous case series, only 75% of patients were alive at the end of the first year of treatment. These findings, led MAS to develop a consensus-derived standardized diagnosis and treatment schema (MAS-ALL18), which takes into account clinical, cytogenetic, and MRD results. Diagnostic testing is performed in a centralized laboratory. Although centred on delivery of standard of care, this experience represents is the first prospective multi-site cooperative group effort in Mexico. We report on early treatment (first 90 days) clinical and implementation outcomes utilizing the MAS-ALL18 adapted management guideline (AMG) in four member hospitals of the MAS collaboration network.

Published
2021
Full Text
View/download PDF

15. BRAF-V600E in Peripheral Mononuclear Cells and Microglia-like Brain Cells Suggest Hematopoietic Origin of Langerhans Cell Histiocytosis-Associated Neurodegeneration

Author

Zinn, Daniel, Picarsic, Jennifer, Chakraborty, Rikhia, Lin, Howard, Abhyankar, Harshal, Scull, Brooks, Shih, Albert, Phaik Har Lim, Karen, Eckstein, Olive S., Peters, Tricia L., Olea, Walter, Burke, Thomas, Ahmed, Nabil, Hicks, John, Tran, Brandon, Jones, Jeremy, Dauser, Robert, Jeng, Michael R., Baiocchi, Robert A, Schiff, Deborah E., Goldman, Stanton, Heym, Kenneth Matthew, Wilson, Harry, Carcamo, Benjamin, Kumar, Ashish, Rodriguez-Galindo, Carlos, Whipple, Nicholas, Campbell, Patrick, Murdoch, Geoffrey, Heales, Simon, Malone, Marian, Woltjer, Randy, Quinn, Joseph, Orchard, Paul, Kruer, Michael, Jaffe, Ronald, Manz, Markus G, Lira, Sergio, Parsons, Donald Will, Merad, Miriam, Man, Tsz-kwong, McClain, Kenneth L., and Allen, Carl E.

Abstract

Introduction:Langerhans cell histiocytosis (LCH) is a myeloid neoplasia characterized by inflammatory lesions with pathologic CD207+ myeloid dendritic cells (DC). Activation of ERKoccurs in all patients with the most common somatic driver mutation being BRAF-V600Ebeing found in up to 60% of patients.Mononuclear cells harboring the BRAF-V600Emutation have been found in peripheral blood of patients with involvement of the liver, spleen, or bone marrow, known as high risk organs. LCH involvement of the brain may include mass lesions in 25% of patients, most commonly the pituitary gland, or a progressive neurodegenerative syndrome (LCH-ND) that arises in approximately 5% of patients. LCH-ND may arise years after the initial LCH episode was presumed to have been cured and may lead to permanent neurologic deficits. The pathogenesis of LCH-ND is poorly understood, but is believed to be due to an autoimmune or paraneoplastic process. No standard approaches to surveillance or therapy exist. In order to define the etiology of LCH-ND, develop clinical tools for identifying patients at risk for LCH-ND, and to identify potential targets for novel therapies, we evaluated cerebral spinal fluid (CSF) proteins, extracellular BRAF- V600EDNA in CSF, and BRAF-V600E+ cells in peripheral blood and brain biopsies.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results